Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 3

1.

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE.

J Clin Oncol. 2012 Jul 10;30(20):2509-15. doi: 10.1200/JCO.2011.41.5869. Epub 2012 Jun 4.

2.

The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.

Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

J Thorac Oncol. 2006 Jul;1(6):591-601. Review.

3.

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.

Levin PA, Dowell JE.

Onco Targets Ther. 2017 Apr 7;10:2057-2066. doi: 10.2147/OTT.S113598. eCollection 2017. Review.

Supplemental Content

Support Center